Bangkok, August 1, 2025 – At the Renaissance Bangkok Ratchaprasong Hotel, more than 60 oncology experts from across Thailand attended the official launch of Zerpidio (serplulimab), a new breakthrough in immunotherapy for lung cancer.
This event highlights the theme: “It's Time to Shift from Evolution to Innovation in SCLC,” marks a paradigm shift in the treatment of small cell lung cancer (SCLC) from gradual progress to innovation that has a real impact on the quality and life expectancy of patients. Zerpidio was developed by Shanghai Henlius Biotech and is now officially marketed in Thailand by Alliance Pharma, a distribution partner of Kalbe International. This partnership is part of Kalbe’s strategy to expand access to innovative and high-quality oncology therapies in Southeast Asia.
High Enthusiasm from the Speakers:
All scientific sessions in this launch were delivered with high enthusiasm and passion by the speakers. The participants responded positively to both the informative material and the engaging presentation style. The speakers who contributed included:
- Associate Professor Thanyanan
Presenting the evolution of lung cancer therapy, from the role of surgery, chemoradiotherapy, PCI, to the position of immunotherapy in limited-stage small cell lung carcinoma (LS-SCLC) in a systematic and easy-to-understand manner.
- Assistant Professor Dr. Pongwut Danchaivijitr
Presenting data from the ASTRUM-005 clinical trial of serplulimab, along with comparisons to other immunotherapies such as atezolizumab (IMpower133) and durvalumab (CASPIAN). He highlighted the potential advantages of serplulimab, which achieved a median overall survival (OS) of up to 15.4 months.
- Professor Zhou Caicun (China)
As a guest of honor, he shared his global experience and perspective on the use of immunotherapy for lung cancer.
- Assistant Professor Lucksamon and Assistant Professor Thanate
Presented real-world cases of advanced lung cancer patients who have used Zerpidio, including cases with brain metastasis, providing a clear picture of its clinical benefits in daily practice.
- Dr. Sven Tang, Chief Medical Officer of KGbio
In his remarks, he stated that “Zerpidio is not just a product, but a symbol of new hope for lung cancer patients and the medical community.”
A Symbol of Innovation for the Future
The launch of Zerpidio is not only a significant milestone for the medical community in Thailand but also reinforces Kalbe and Alliance Pharma’s commitment to delivering science-based therapeutic solutions that are more widely accessible to patients in Southeast Asia.
With a spirit of collaboration and innovation, this event underscores that it is time to move beyond mere evolution toward real innovation in lung cancer treatment.
